167 related articles for article (PubMed ID: 25966555)
41. The effects of mPEG proportion and LA/GA ratio on degradation and drug release behaviors of PLGA-mPEG microparticles.
Shi C; Liu P; Liu X; Feng X; Fu D
Pharmazie; 2016 May; 71(5):243-6. PubMed ID: 27348966
[TBL] [Abstract][Full Text] [Related]
42. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
[TBL] [Abstract][Full Text] [Related]
43. Dopamine-conjugated poly(lactic-co-glycolic acid) nanoparticles for protein delivery to macrophages.
Lee SY; Cho HJ
J Colloid Interface Sci; 2017 Mar; 490():391-400. PubMed ID: 27914338
[TBL] [Abstract][Full Text] [Related]
44. Poly(ester anhydride)/mPEG amphiphilic block co-polymer nanoparticles as delivery devices for paclitaxel.
Liang Y; Xiao L; Li Y; Zhai Y; Xie C; Deng L; Dong A
J Biomater Sci Polym Ed; 2011; 22(4-6):701-15. PubMed ID: 20566053
[TBL] [Abstract][Full Text] [Related]
45. Biodegradable polymersomes with an ionizable membrane: facile preparation, superior protein loading, and endosomal pH-responsive protein release.
Li S; Meng F; Wang Z; Zhong Y; Zheng M; Liu H; Zhong Z
Eur J Pharm Biopharm; 2012 Sep; 82(1):103-11. PubMed ID: 22691417
[TBL] [Abstract][Full Text] [Related]
46. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
47. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
48. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance.
Zhu H; Chen H; Zeng X; Wang Z; Zhang X; Wu Y; Gao Y; Zhang J; Liu K; Liu R; Cai L; Mei L; Feng SS
Biomaterials; 2014 Feb; 35(7):2391-400. PubMed ID: 24360574
[TBL] [Abstract][Full Text] [Related]
49. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
50. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Yang A; Yang L; Liu W; Li Z; Xu H; Yang X
Int J Pharm; 2007 Feb; 331(1):123-32. PubMed ID: 17097246
[TBL] [Abstract][Full Text] [Related]
51. Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro.
Ma J; Shen M; Xu CS; Sun Y; Duan YR; Du LF
Oncotarget; 2016 Nov; 7(48):80008-80018. PubMed ID: 27835907
[TBL] [Abstract][Full Text] [Related]
52. Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy.
Xiong W; Peng L; Chen H; Li Q
Int J Nanomedicine; 2015; 10():2985-96. PubMed ID: 25945046
[TBL] [Abstract][Full Text] [Related]
53. BSA-FITC-loaded microcapsules for in vivo delivery.
Kim BS; Oh JM; Kim KS; Seo KS; Cho JS; Khang G; Lee HB; Park K; Kim MS
Biomaterials; 2009 Feb; 30(5):902-9. PubMed ID: 19027943
[TBL] [Abstract][Full Text] [Related]
54. [In vitro study on polyethylene glycol-chitosan copolymer as a gene delivery vector].
Zhang W; Pan SR; Zhang X; Luo X; Wang C
Yao Xue Xue Bao; 2008 Aug; 43(8):848-54. PubMed ID: 18956779
[TBL] [Abstract][Full Text] [Related]
55. Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin.
Gryparis EC; Mattheolabakis G; Bikiaris D; Avgoustakis K
Drug Deliv; 2007 Aug; 14(6):371-80. PubMed ID: 17701526
[TBL] [Abstract][Full Text] [Related]
56. Preparation and Characterization of Copolymeric Polymersomes for Protein Delivery.
Nomani A; Nosrati H; Manjili HK; Khesalpour L; Danafar H
Drug Res (Stuttg); 2017 Aug; 67(8):458-465. PubMed ID: 28561240
[TBL] [Abstract][Full Text] [Related]
57. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
58. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
59. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.
Wang Y; Liu P; Du J; Sun Y; Li F; Duan Y
J Biomater Sci Polym Ed; 2013; 24(10):1219-32. PubMed ID: 23713424
[TBL] [Abstract][Full Text] [Related]
60. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer.
Xing L; Shi Q; Zheng K; Shen M; Ma J; Li F; Liu Y; Lin L; Tu W; Duan Y; Du L
Theranostics; 2016; 6(10):1573-87. PubMed ID: 27446491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
